Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024
ADVANCED SEARCH
Log in
Top
Pulmonary Therapy
Published in:

Open Access 08-11-2024 | Chronic Obstructive Lung Disease | Review

Do Antidepressants Worsen COPD Outcomes in Depressed Patients with COPD?

Author: Alan G. Kaplan

Published in: Pulmonary Therapy | Issue 4/2024

Login to get access

Abstract

The coexistence of depression with chronic obstructive pulmonary disease (COPD) has been associated with poorer outcomes. Studies have questioned the safety of antidepressants in patients with COPD. This review shows the potential relationships and the possible mechanisms and gives us good warnings on how to approach this problem. Treatment should be both non-pharmacological and pharmacological, but importantly tailored to the individual patient.
Literature
1.
2.
3.
4.
Singh G, Zhang W, Kuo Y-F, et al. Association of psychological disorders with 30-day readmission rates in patients with COPD. Chest. 2016;149:905–15.PubMedPubMedCentralCrossRef
5.
Lyer AS, Bhatt SP, Garner JJ, et al. Depression is associated with readmission for acute exacerbation of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2016;13:197–203.CrossRef
6.
7.
van Ede L, Yzermans CJ, Brouwer HJ. Prevalence of depression in patients with chronic obstructive pulmonary disease: a systematic review. Thorax. 1999;54:688–92.PubMedPubMedCentralCrossRef
8.
Hynninen KM, Breitve MH, Wiborg AB, Pallesen S, Nordhus IH. Psychological characteristics of patients with chronic obstructive pulmonary disease: a review. J Psychosom Res. 2005;59:429–43.PubMedCrossRef
9.
Brenes GA. Anxiety and chronic obstructive pulmonary disease: prevalence, impact, and treatment. Psychosom Med. 2003;65:963–70.PubMedCrossRef
10.
Mikkelsen RL, Middelboe T, Pisinger C, Stage KB. Anxiety and depression in patients with chronic obstructive pulmonary disease (COPD). A review. Nord J Psychiatry. 2004;58:65–70.PubMedCrossRef
11.
12.
13.
14.
15.
16.
17.
Arabyat RM, Raisch DW. Relationships between social/emotional support and quality of life, depression and disability in patients with chronic obstructive pulmonary disease: an analysis based on propensity score matching. Ann Behav Med. 2019;20:1–10.
18.
Yohannes AM, Baldwin RC, Connolly MJ. Depression and anxiety in elderly patients with chronic obstructive pulmonary disease. Age Ageing. 2006;35:457–9.PubMedCrossRef
19.
Yohannes AM. Depression and COPD in older people: a review and discussion. Br J Community Nurs. 2005;10:42–6.PubMedCrossRef
20.
Collins PF, Stratton RJ, Kurukulaaratchy RJ, et al. Influence of deprivation on health care use, healthcare costs, and mortality in COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:1289–96.PubMedPubMedCentralCrossRef
21.
Marti S, Muñoz X, Rios J, et al. Body weight and comorbidity predict mortality in COPD patients treated with oxygen therapy. Eur Respir J. 2006;27:689–96.PubMedCrossRef
22.
Laforest L, Roche N, Devouassoux G, et al. Frequency of comorbidities in chronic obstructive pulmonary disease, and impact on all-cause mortality: a population-based cohort study. Respir Med. 2016;117:33–9.PubMedCrossRef
23.
Ng TP, Niti M, Tan WC, Cao Z, Ong KC, Eng P. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med. 2007;167:60–7.PubMedCrossRef
24.
Kim HF, Kunik ME, Molinari VA, et al. Functional impairment in COPD patients:the impact of anxiety and depression. Psychosomatics. 2000;41:465–71.PubMedCrossRef
25.
26.
27.
28.
29.
Wilkinson TM, Donaldson GC, Hurst JR, Seemungal TA, Wedzicha JA. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;169:1298–303.PubMedCrossRef
30.
Eiser N, Harte R, Spiros K, Phillips C, Isaac MT. Effect of treating depression on quality-of-life and exercise tolerance in severe COPD. COPD. 2005;2:233–41.PubMedCrossRef
31.
Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P, Hasnain M, Jollant F, Levitt AJ, MacQueen GM, McInerney SJ, McIntosh D, Milev RV, Müller DJ, Parikh SV, Pearson NL, Ravindran AV, Uher R; CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. Can J Psychiatry. 2016;61(9):540–60. https://​doi.​org/​10.​1177/​0706743716659417​. Epub 2016 Aug 2. Erratum in: Can J Psychiatry. 2017;62(5):356
32.
Yohannes AM, Connolly MJ, Baldwin RC. A feasibility study of antidepressant drug therapy in depressed elderly patients with chronic obstructive pulmonary disease. Int J Geriatr Psychiatry. 2001;16:451–4.PubMedCrossRef
33.
Vozoris NT, Wang X, Austin PC, et al. Serotonergic antidepressant use and morbidity and mortality among older adults with COPD. Eur Respir J 2018;52:1800475. 10.1183/ 13993003.00475-2018
34.
Hennessy S, Bilker WB, Leonard CE, et al. Observed association between antidepressant use and pneumonia risk was confounded by comorbidity measures. J Clin Epidemiol. 2007;60:911–8.PubMedPubMedCentralCrossRef
35.
36.
37.
Shenoy AR, Dehmel T, Stettner M, et al. Citalopram suppresses Thymocyte cytokine production. J Neuroimmunol 2013;262:S0165–5728(13)00165–3:46–52
38.
Taler M, Gil-Ad I, Lomnitski L, et al. Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur Neuropsychopharmacol. 2007;17:774–80.PubMedCrossRef
39.
Pellegrino TC, Bayer BM. Specific serotonin reuptake inhibitor-induced decreases in lymphocyte activity require endogenous serotonin release. Neuroimmunomodulation. 2000;8:179–87.PubMedCrossRef
40.
Fazzino F, Montes C, Urbina M, et al. Serotonin transporter is differentially localized in subpopulations of lymphocytes of major depression patients. Effect of fluoxetine on proliferation. J Neuroimmunol. 2008;196:173–80.PubMedCrossRef
41.
42.
Berlin I, Covey LS. Pre-cessation depressive mood predicts failure to quit smoking: the role of coping and personality traits. Addiction. 2006;101:1814–21.PubMedCrossRef
43.
Lembke A, Johnson K, DeBattista C. Depression and smoking cessation: does the evidence support psychiatric practice? Neuropsychiatr Dis Treat. 2007;3(4):487–93.PubMedPubMedCentral
44.
45.
46.
47.
Chatterjee S, Carnahan RM, Chen H, et al. Anticholinergic medication use and risk of pneumonia in elderly adults: a nested case-control study. J Am Geriatr Soc. 2016;64:394–400.PubMedCrossRef
48.
49.
50.
Smoller JW, Pollack MH, Otto MW, Rosenbaum JF, Kradin RL. Panic anxiety, dyspnea, and respiratory disease. Theoretical and clinical considerations. Am J Respir Crit Care Med. 1996;154:6–17.PubMedCrossRef
51.
Patton GC, Hibbert M, Rosier MJ, Carlin JB, Caust J, Bowes G. Is smoking associated with depression and anxiety in teenagers? Am J Public Health. 1996;86:225–30.PubMedPubMedCentralCrossRef
52.
Breslau N, Kilbey MM, Andreski P. Nicotine withdrawal symptoms and psychiatric disorders: findings from an epidemiologic study of young adults. Am J Psychiatry. 1992;149:464–9.PubMedCrossRef
53.
54.
55.
56.
57.
58.
59.
60.
61.
Vozoris NT, Fischer HD, Wang X, et al. Benzodiazepine drug use and adverse respiratory outcomes among older adults with COPD. Eur Respir J. 2014;44:332–40.PubMedCrossRef
62.
Battaglia S, Bezzi M, Sferrazza Papa GF. Are benzodiazepines and opioids really safe in patients with severe COPD? Minerva Med. 2014;105(6 Suppl 3):1–7.PubMed
63.
64.
65.
Vozoris NT, Wang X, Fischer HD, et al. Incident opioid drug use and adverse respiratory outcomes among older adults with COPD. Eur Respir J. 2016;8:683–93.CrossRef
66.
67.
68.
Rahman AA, Dell’Aniello S, Moodie EEM, Durand M, Coulombe J, Boivin JF, Suissa S, Ernst P, Renoux C. Gabapentinoids and risk for severe exacerbation in chronic obstructive pulmonary disease : a population-based cohort study. Ann Intern Med. 2024;177(2):144–54. https://​doi.​org/​10.​7326/​M23-0849.CrossRefPubMed
69.
Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med. 1998;338:1516–20.PubMedCrossRef
70.
Kunik ME, Roundy K, Veazey C, et al. surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest. 2005;127:1205–11.PubMed
71.
Lacasse Y, Rousseau L, Maltais F. Prevalence of depressive symptoms and depression in patients with severe oxygen-dependent chronic obstructive pulmonary disease. J Cardiopulm Rehabil. 2001;21:80–6.PubMedCrossRef
72.
Gilbody S, House AO, Sheldon TA. Screening and case finding instruments for depression. Cochrane Database Syst Rev 2005; CD002792.
73.
Williams JW Jr, Noel PH, Cordes JA, Ramirez G, Pignone M. Is this patient clinically depressed? JAMA. 2002;287:1160–70.PubMedCrossRef
74.
Mulrow CD, Williams JW Jr, Gerety MB, Ramirez G, Montiel OM, Kerber C. Case-finding instruments for depression in primary care settings. Ann Intern Med. 1995;122:913–21.PubMedCrossRef
75.
76.
Yohannes AM, Müllerová H, Hanania NA, et al. Long-term course of depression trajectories in patients with COPD: A 3-year follow-up analysis of the evaluation of COPD longitudinally to identify predictive surrogate endpoints cohort. Chest. 2016;149:916–26.PubMedCrossRef
77.
Hill K, Geist R, Goldstein RS, et al. Anxiety and depression in end-stage COPD. Eur Respir J. 2008;31:667–77.PubMedCrossRef
78.
Maurer J, Rebbapragda V, Borson S, et al. ACCP workshop panel on anxiety and depression in COPD. Anxiety and depression in COPD: current understanding, unanswered questions and research needs. Chest 2008;134:Suppl. 4, 43S–56S.
79.
80.
Fennell M. Cognitive behaviour therapy for depressive disorders. In: Gelder M, Andreasen N, Lopez-Ibor J, Geddes J, editors. New Oxford Textbook of Psychiatry. New York: Oxford University Press; 2012. p. 1304–12.
81.
Pampallona S, Bollini P, Tibaldi G, Kupelnick B, Munizza C. Combined pharmacotherapy and psychological treatment for depression: a systematic review. Arch Gen Psychiatry. 2004;61:714–9.PubMedCrossRef
82.
Lacasse Y, Wong E, Guyatt GH, King D, Cook DJ, Goldstein RS. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. Lancet. 1996;348:1115–9.PubMedCrossRef
83.
Paz-Diaz H, Montes de Oca M, Lopez JM, Celli BR. Pulmonary rehabilitation improves depression, anxiety, dyspnea and health status in patients with COPD. Am J Phys Med Rehabil 2007;86:30–36.
84.
de Godoy DV, de Godoy RF. A randomized controlled trial of the effect of psychotherapy on anxiety and depression in chronic obstructive pulmonary disease. Arch Phys Med Rehabil. 2003;84:1154–7.PubMed
85.
Kunik ME, Braun U, Stanley MA, et al. One session cognitive behavioural therapy for elderly patients with chronic obstructive pulmonary disease. Psychol Med. 2001;31:717–23.PubMedCrossRef
86.
Gallo JJ, Morales KH, Bogner HR, et al. Long term effect of depression care management on mortality in older adults: follow-up of cluster randomized controlled trial in primary care. BMJ. 2013;346: f2570.PubMedPubMedCentralCrossRef
87.
88.
89.
90.
91.
92.
93.
Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, Ritz L, Nierenberg AA, Lebowitz BD, Biggs MM, Luther JF, Shores-Wilson K, Rush AJ, STAR*D Study Team. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354(12):1243–52. https://​doi.​org/​10.​1056/​NEJMoa052964.CrossRefPubMed
94.
95.
96.
97.
98.
Garuti G, Cilione C, Dell’Orso D, et al. Impact of comprehensive pulmonary rehabilitation on anxiety and depression in hospitalized COPD patients. Monaldi Arch Chest Dis. 2003;59:56–61.PubMed
99.
100.
101.
Metadata
Title
Do Antidepressants Worsen COPD Outcomes in Depressed Patients with COPD?
Author
Alan G. Kaplan
Publication date
08-11-2024
Publisher
Springer Healthcare
Published in
Pulmonary Therapy / Issue 4/2024
Print ISSN: 2364-1754
Electronic ISSN: 2364-1746
DOI
https://doi.org/10.1007/s41030-024-00277-9

Other articles of this Issue 4/2024

Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

A Retrospective, Longitudinal Registry Study on the Long-Term Durability of Ivacaftor Treatment in People with Cystic Fibrosis

Perspectives on Drug Product Design Among Patients with Lung Cancer in the United Kingdom

Is ‘Cardiopulmonary’ the New ‘Cardiometabolic’? Making a Case for Systems Change in COPD

Efficacy of High Flow Nasal Cannula in the Treatment of Patients with COVID-19 with Acute Respiratory Distress Syndrome: Results of Single Centre Study in Vietnam

  • Open Access
  • COVID-19
  • Original Research

Comparison of Reporting Quality in National Cystic Fibrosis Patient Registries: Implications for Identifying Use of Novel CFTR Modulators

Keynote webinar | Spotlight on adolescent vaping

  • Live
  • Webinar | 29-01-2025 | 18:00 (CET)

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Watch it live: Wednesday 29th January, 18:00-19:30 CET
 

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Join the webinar
SPONSORED

Targeting COPD with type 2 inflammation: emerging biologic landscape

  • Webinar | 03-12-2024 | 19:00 (CET)

Join us for an insightful session tailored for pulmonologists and healthcaree professionals eager to enhance their understanding of COPD and the latest advances in biologic therapies. 

On-demand version coming soon

Sponsored by:
  • Sanofi
Developed by: Springer Healthcare
Learn more

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases
Image Credits